Case and Research Letters
Hand-Foot Skin Reaction to Regorafenib
Reacción cutánea mano-pie por regorafenib
P. Espinosa Laraa,
, C. Bueno Muiñob, B. Doger de Spévilleb, J. Jiménez Reyesc
Autor para correspondencia
a Servicio de Dermatología, Unidad de Oncodermatología, Consulta de efectos adversos por antineoplásicos, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
b Servicio de Oncología Médica, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
c Servicio de Dermatología, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain
Leído
6843
Vecesse ha leído el artículo
2315
Total PDF
4528
Total HTML
Compartir estadísticas
array:24 [ "pii" => "S1578219015003145" "issn" => "15782190" "doi" => "10.1016/j.adengl.2015.11.005" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1211" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2014" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2016;107:71-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1003 "formatos" => array:3 [ "EPUB" => 47 "HTML" => 611 "PDF" => 345 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731015002823" "issn" => "00017310" "doi" => "10.1016/j.ad.2015.03.016" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1211" "copyright" => "Elsevier España, S.L.U. y AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2016;107:71-3" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 499 "formatos" => array:3 [ "EPUB" => 3 "HTML" => 362 "PDF" => 134 ] ] "es" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">CARTA CIENTÍFICO-CLÍNICA</span>" "titulo" => "Reacción cutánea mano-pie por regorafenib" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "73" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Hand-Foot Skin Reaction to Regorafenib" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figura 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 574 "Ancho" => 990 "Tamanyo" => 107036 ] ] "descripcion" => array:1 [ "es" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Eritema y leve descamación en ambas palmas.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "P. Espinosa Lara, C. Bueno Muiño, B. Doger de Spéville, J. Jiménez Reyes" "autores" => array:4 [ 0 => array:2 [ "nombre" => "P." "apellidos" => "Espinosa Lara" ] 1 => array:2 [ "nombre" => "C." "apellidos" => "Bueno Muiño" ] 2 => array:2 [ "nombre" => "B." "apellidos" => "Doger de Spéville" ] 3 => array:2 [ "nombre" => "J." "apellidos" => "Jiménez Reyes" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219015003145" "doi" => "10.1016/j.adengl.2015.11.005" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015003145?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015002823?idApp=UINPBA000044" "url" => "/00017310/0000010700000001/v1_201512300105/S0001731015002823/v1_201512300105/es/main.assets" ] ] "itemSiguiente" => array:18 [ "pii" => "S1578219015003224" "issn" => "15782190" "doi" => "10.1016/j.adengl.2015.11.013" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1214" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2016;107:73-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 693 "formatos" => array:3 [ "EPUB" => 34 "HTML" => 451 "PDF" => 208 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Eccrine Carcinoma: The role of Mohs Micrographic Surgery and Review of the Literature" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "73" "paginaFinal" => "76" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Carcinoma ductal ecrino: papel de la cirugía de Mohs y revisión de la literatura" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0015" "etiqueta" => "Figure 3" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr3.jpeg" "Alto" => 1446 "Ancho" => 1400 "Tamanyo" => 372174 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Clinical images. A, Design of the rotation flap on the cheek. B, Result immediately after surgery. Rotation flap and Burow graft. C, Lateral view. Result 45 days after surgery. D, Frontal view. Result 45 days after surgery.</p>" ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "M. Lorente-Luna, E. Jiménez Blázquez, C. Sánchez Herreros, J. Cuevas Santos" "autores" => array:4 [ 0 => array:2 [ "nombre" => "M." "apellidos" => "Lorente-Luna" ] 1 => array:2 [ "nombre" => "E. Jiménez" "apellidos" => "Blázquez" ] 2 => array:2 [ "nombre" => "C. Sánchez" "apellidos" => "Herreros" ] 3 => array:2 [ "nombre" => "J. Cuevas" "apellidos" => "Santos" ] ] ] ] ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015003224?idApp=UINPBA000044" "url" => "/15782190/0000010700000001/v2_201704190205/S1578219015003224/v2_201704190205/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219015003157" "issn" => "15782190" "doi" => "10.1016/j.adengl.2015.11.006" "estado" => "S300" "fechaPublicacion" => "2016-01-01" "aid" => "1197" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2016;107:70" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 1335 "formatos" => array:3 [ "EPUB" => 52 "HTML" => 1040 "PDF" => 243 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => "My Daughter's Hair Won’t Grow" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "70" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "A mi hija no le crece el pelo" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 800 "Ancho" => 841 "Tamanyo" => 145087 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "N. Knöpfel, A. Martín-Santiago" "autores" => array:2 [ 0 => array:2 [ "nombre" => "N." "apellidos" => "Knöpfel" ] 1 => array:2 [ "nombre" => "A." "apellidos" => "Martín-Santiago" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731015002665" "doi" => "10.1016/j.ad.2015.04.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731015002665?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015003157?idApp=UINPBA000044" "url" => "/15782190/0000010700000001/v2_201704190205/S1578219015003157/v2_201704190205/en/main.assets" ] "en" => array:15 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case and Research Letters</span>" "titulo" => "Hand-Foot Skin Reaction to Regorafenib" "tieneTextoCompleto" => true "saludo" => "<span class="elsevierStyleItalic">To the Editor:</span>" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "71" "paginaFinal" => "73" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "P. Espinosa Lara, C. Bueno Muiño, B. Doger de Spéville, J. Jiménez Reyes" "autores" => array:4 [ 0 => array:4 [ "nombre" => "P. Espinosa" "apellidos" => "Lara" "email" => array:1 [ 0 => "pablo.e.lara@outlook.es" ] "referencia" => array:2 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "aff0005" ] 1 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] 1 => array:3 [ "nombre" => "C. Bueno" "apellidos" => "Muiño" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 2 => array:3 [ "nombre" => "B. Doger de" "apellidos" => "Spéville" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">b</span>" "identificador" => "aff0010" ] ] ] 3 => array:3 [ "nombre" => "J. Jiménez" "apellidos" => "Reyes" "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">c</span>" "identificador" => "aff0015" ] ] ] ] "afiliaciones" => array:3 [ 0 => array:3 [ "entidad" => "Servicio de Dermatología, Unidad de Oncodermatología, Consulta de efectos adversos por antineoplásicos, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain" "etiqueta" => "a" "identificador" => "aff0005" ] 1 => array:3 [ "entidad" => "Servicio de Oncología Médica, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain" "etiqueta" => "b" "identificador" => "aff0010" ] 2 => array:3 [ "entidad" => "Servicio de Dermatología, Hospital Universitario Infanta Cristina, Parla, Madrid, Spain" "etiqueta" => "c" "identificador" => "aff0015" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Reacción cutánea mano-pie por regorafenib" ] ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 574 "Ancho" => 990 "Tamanyo" => 103824 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Erythema and mild desquamation on the palms.</p>" ] ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">In recent years, the appearance of targeted drugs has revolutionized treatment in the field of oncology. With these drugs, the profile of systemic side effects is different than in conventional chemotherapy and the need for dosage suspension is smaller, but skin reactions are more frequent and often have an effect on adherence. Among these drugs is regorafenib, a multikinase inhibitor that was recently approved for the treatment of metastatic colorectal cancer. The hand-foot skin reaction is one of the most common toxicities of this drug.</p><p id="par0010" class="elsevierStylePara elsevierViewall">We report the case of a 69-year-old man diagnosed in 2012 with stage <span class="elsevierStyleSmallCaps">IV</span> rectal adenocarcinoma with liver and lung metastases and wild-type K-RAS, for which he had received chemotherapy according to the XELOX-Avastin treatment regimen (capecitabine, oxaliplatin, and bevacizumab), with progression in the liver after 13 cycles of treatment. He subsequently received treatment with FOLFIRI-Erbitux (irinotecan, 5-fluorouracil, and cetuximab), with progression in the liver and lungs after 12 cycles. Grade 2 palmar-plantar erythrodysesthesia occurred as a side effect and was initially attributed to the capecitabine treatment. When only residual erythema remained on the palms and soles, the lesions reappeared after the introduction of 5-fluorouracil. The patient also had grade 2 neuropathy, secondary to the oxaliplatin treatment, which persisted at grade 1 at the start of the regorafenib treatment. Two months later, in light of the progression of the disease with FOLFIRI-Erbitux treatment, treatment with regorafenib was started at a dose of 160<span class="elsevierStyleHsp" style=""></span>mg/d. At 2 weeks, the patient reported an increase in erythema on the palms and soles and the appearance of keratotic lesions on the weight-bearing surfaces of both feet (<a class="elsevierStyleCrossRefs" href="#fig0005">Figs. 1 and 2</a>). Physical examination revealed poorly defined areas of erythema on the palms, with more intense involvement of the thenar and hypothenar eminences (<a class="elsevierStyleCrossRef" href="#fig0005">Fig. 1</a>), and erythema with diffuse desquamation that covered practically the entire surface of both soles, with keratotic papules that were mildly painful to the touch in the weight-bearing areas of the balls of the feet, distributed symmetrically and bilaterally (<a class="elsevierStyleCrossRef" href="#fig0010">Fig. 2</a>). After diagnosis of regorafenib-induced hand-foot skin reaction, treatment was prescribed with emollients on the palms and soles, as well as curettage and the application of 30% urea to the keratotic regions. Clinical course was good and the pain disappeared, although the erythema persisted. To date, the patient has received 2 cycles of regorafenib, with optimal doses and no need for delays or suspension of treatment.</p><elsevierMultimedia ident="fig0005"></elsevierMultimedia><elsevierMultimedia ident="fig0010"></elsevierMultimedia><p id="par0015" class="elsevierStylePara elsevierViewall">Regorafenib (Stivarga, Bayer HealthCare Pharmaceuticals) is a new oral multikinase inhibitor<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> that targets cell-signaling pathways involved in angiogenesis (VEGFR1–3, TIE2), oncogenesis (KIT, RET, RAF), and the maintenance of the tumor microenvironment (PDGFR and FGFR).<a class="elsevierStyleCrossRef" href="#bib0055"><span class="elsevierStyleSup">1</span></a> It is indicated for the treatment of metastatic colorectal cancer in adult patients who have previously received treatment or are not candidates for other lines of chemotherapy, and in patients with gastrointestinal stromal tumors (GISTs) who are not candidates for surgery and who have not responded to other treatments (imatinib, sunitinib). Regorafenib is also being investigated for use in other types of cancer.<a class="elsevierStyleCrossRefs" href="#bib0060"><span class="elsevierStyleSup">2,3</span></a> The recommended dosage is a single dose of 160<span class="elsevierStyleHsp" style=""></span>mg each day for 3 weeks, followed by 1 week off. Each 4-week period is considered a treatment cycle. Treatment continues as long as it obtains therapeutic benefits or until unacceptable toxicity appears.<a class="elsevierStyleCrossRef" href="#bib0060"><span class="elsevierStyleSup">2</span></a> Regorafenib was approved for the treatment of metastatic colorectal adenocarcinoma following the publication of the results of a phase <span class="elsevierStyleSmallCaps">iii</span> clinical trial named CORRECT, which compared regorafenib to placebo in patients with colorectal adenocarcinoma whose disease had progressed despite having received the standard antineoplastic therapy. In that study, the most common cutaneous side effect was the hand-foot skin reaction, which affected 46.6% of the 760 randomized patients (16.6% of whom had a grade 3 reaction)<span class="elsevierStyleSup">4</span>–higher rates than those seen with other multikinase inhibitors such as sorefenib.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> Other common side effects were asthenia (47.7% of patients, 9.2% grade 3), hypertension (27.8%), and diarrhea (33.8%).<a class="elsevierStyleCrossRef" href="#bib0070"><span class="elsevierStyleSup">4</span></a></p><p id="par0020" class="elsevierStylePara elsevierViewall">In a 2013 meta-analysis by Belum et al<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a> that included 1078 patients with colorectal adenocarcinoma, GISTs, renal cell carcinoma, and hepatocellular carcinoma who received treatment with regorafenib, the overall incidence of the hand-foot skin reaction was 60.5% (range in the various studies, 46.6%-84.8%). The lowest incidence (46.6%) was observed in a multicenter phase <span class="elsevierStyleSmallCaps">iii</span> trial with 500 patients with metastatic renal carcinoma, and the highest incidence (84.8%) was reported in a multicenter phase <span class="elsevierStyleSmallCaps">ii</span> trial with 33 patients with GISTs.<a class="elsevierStyleCrossRef" href="#bib0065"><span class="elsevierStyleSup">3</span></a></p><p id="par0025" class="elsevierStylePara elsevierViewall">The precise molecular mechanism by which the hand-foot skin reaction is caused by multikinase inhibitors such as sorafenib–or, in our case, regorafenib–is unknown. According to one hypothesis, a class effect could be caused by direct cytotoxicity of the drug and a defect in cell repair caused by inhibition of PDGFR.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5,6</span></a> This effect would manifest as very painful and incapacitating hyperkeratotic lesions on pressure or friction points on the palms and soles and would be exacerbated by trauma. The effect is dose-dependent and can be associated with the appearance of edema and blisters (grades 2 and 3). Histopathologic findings that have been described include epidermal parakeratosis and dyskeratosis with vacuolar degeneration of the keratinocytes, the presence of intracytoplasmic eosinophilic bodies, and blister formation in the Malpighian layer.<a class="elsevierStyleCrossRefs" href="#bib0075"><span class="elsevierStyleSup">5,6</span></a> A dense superficial and perivascular lymphocytic inflammatory infiltrate with some degree of nonleukocytoclastic vasculitis is observed in the dermis.<a class="elsevierStyleCrossRef" href="#bib0075"><span class="elsevierStyleSup">5</span></a> Treatment consists of keratolytic agents (30%-40% urea, salicylic acid) plus prophylactic measures (preventive offloading with adapted orthopedic insoles, podiatric care, etc.), and analgesia. Early introduction of these measures can help make it possible to maintain antineoplastic therapy at optimal doses and prevent delays or withdrawal of treatment.<a class="elsevierStyleCrossRefs" href="#bib0085"><span class="elsevierStyleSup">7,8</span></a></p><p id="par0030" class="elsevierStylePara elsevierViewall">It is important to differentiate this effect from hand-foot syndrome, also known as palmar-plantar erythrodysesthesia or chemotherapy-induced acral erythema (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a> This syndrome appears in patients who receive conventional chemotherapy such as liposomal doxorubicin, capecitabine, or cytarabine and is associated with erythema, variable desquamation and edema, and even fissuring and blistering. Both entities are dose-dependent, and in both cases cytotoxicity is the most likely pathophysiological mechanism. In the hand-foot skin reaction, however, hyperkeratosis is more frequent, appears earlier, is patchier, and can be the only manifestation.<a class="elsevierStyleCrossRefs" href="#bib0080"><span class="elsevierStyleSup">6,10</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0035" class="elsevierStylePara elsevierViewall">This is the first case of hand-foot skin reaction secondary to regorafenib to be reported in the Spanish medical literature. Dermatologists should be aware of this entity and be able to diagnose it as part of the multidisciplinary management of the cutaneous side effects of new antineoplastic drugs, because managing these effects is important to ensuring adherence to treatment and optimizing the clinical response to therapy.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Lara PE, Muiño CB, Spéville BDd, Reyes JJ. Reacción cutánea mano-pie por regorafenib. Actas Dermosifiliogr. 2016;107:70–72.</p>" ] ] "multimedia" => array:3 [ 0 => array:7 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 574 "Ancho" => 990 "Tamanyo" => 103824 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Erythema and mild desquamation on the palms.</p>" ] ] 1 => array:7 [ "identificador" => "fig0010" "etiqueta" => "Figure 2" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr2.jpeg" "Alto" => 1072 "Ancho" => 990 "Tamanyo" => 227897 ] ] "descripcion" => array:1 [ "en" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Hyperkeratotic papules on weight-bearing surfaces of the balls of the feet.</p>" ] ] 2 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "fuente" => "Source: Adapted from V. Sanz Motilva.<a class="elsevierStyleCrossRef" href="#bib0095"><span class="elsevierStyleSup">9</span></a>" "tabla" => array:1 [ "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><thead title="thead"><tr title="table-row"><th class="td" title="table-head " align="" valign="top" scope="col" style="border-bottom: 2px solid black"> \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Hand-Foot Syndrome \t\t\t\t\t\t\n \t\t\t\t</th><th class="td" title="table-head " align="left" valign="top" scope="col" style="border-bottom: 2px solid black">Hand-Foot Skin Reaction \t\t\t\t\t\t\n \t\t\t\t</th></tr></thead><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Causative agents \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Conventional chemotherapy (5-fluorouracil and derivatives, cytarabine, liposomal doxorubicin, etc.). \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Multikinase inhibitors (sorafenib, sunitinib, vemurafenib, dabrafenib, regorafenib, etc.). \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Clinical manifestations \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Diffuse erythema and edema, fissures, desquamation, and blisters. Symmetrical. Worsens over time. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Erythematous papules and plaques with a peripheral halo in areas of pressure or friction. Marked hyperkeratosis. Improves over time. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Dose dependence \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Yes \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">Histopathology \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Interface dermatitis.<br>Variable edema.<br>Epidermal detachment.<br>Epidermal dysmaturation.<br>Necrotic keratinocytes<span class="elsevierStyleHsp" style=""></span>±<span class="elsevierStyleHsp" style=""></span>eccrine squamous syringometaplasia.<br>Mild inflammatory infiltrate. \t\t\t\t\t\t\n \t\t\t\t</td><td class="td" title="table-entry " align="left" valign="top">Epidermal hyperplasia.<br>Acanthosis, hyperkeratosis, and focal parakeratosis.<br>Intraepidermal edema.<br>Necrotic keratinocytes.<br>Interface dermatitis. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1396707.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0015" class="elsevierStyleSimplePara elsevierViewall">Hand-Foot Syndrome vs Hand-Foot Skin Reaction.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0005" "bibliografiaReferencia" => array:10 [ 0 => array:3 [ "identificador" => "bib0055" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regorafenib (BAY 73-4506): A new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "S.M. Wilhelm" 1 => "J. Dumas" 2 => "L. Adnane" 3 => "M. Lynch" 4 => "C.A. Carter" 5 => "G. Schütz" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:5 [ "tituloSerie" => "Int J Cancer J Int Cancer." "fecha" => "2011" "volumen" => "129" "paginaInicial" => "245" "paginaFinal" => "255" ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0060" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "European Medicines Agency. Stivarga (regorafenib) [Internet] htttp://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002573/human_med_001684.jsp∣=WC0b01ac058001d124. Accessed November 21, 2014." ] ] ] 2 => array:3 [ "identificador" => "bib0065" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: A meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:3 [ 0 => "V.R. Belum" 1 => "S. Wu" 2 => "M.E. Lacouture" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s10637-013-9977-0" "Revista" => array:7 [ "tituloSerie" => "Invest New Drugs." "fecha" => "2013" "volumen" => "31" "paginaInicial" => "1078" "paginaFinal" => "1086" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23700287" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109704000038" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0070" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase 3 trial" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "A. Grothey" 1 => "E. van Cutsem" 2 => "A. Sobrero" 3 => "S. Siena" 4 => "A. Falcone" 5 => "M. Ychou" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(12)61900-X" "Revista" => array:6 [ "tituloSerie" => "Lancet." "fecha" => "2013" "volumen" => "381" "paginaInicial" => "303" "paginaFinal" => "312" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/23177514" "web" => "Medline" ] ] ] ] ] ] ] ] 4 => array:3 [ "identificador" => "bib0075" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prospective study of the cutaneous adverse effects of sorafenib, a novel multikinase inhibitor" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:5 [ 0 => "J. Autier" 1 => "B. Escudier" 2 => "J. Wechsler" 3 => "A. Spatz" 4 => "C. Robert" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1001/archderm.144.7.886" "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol." "fecha" => "2008" "volumen" => "144" "paginaInicial" => "886" "paginaFinal" => "892" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18645140" "web" => "Medline" ] ] ] ] ] ] ] ] 5 => array:3 [ "identificador" => "bib0080" "etiqueta" => "6" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Reacción cutánea palmoplantar secundaria a sorafenib" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "B. Echeverría" 1 => "B. Llombart" 2 => "R. Botella-Estrada" 3 => "C. Guillén" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermo-Sifiliográficas." "fecha" => "2009" "volumen" => "100" "paginaInicial" => "736" "paginaFinal" => "737" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/19775561" "web" => "Medline" ] ] ] ] ] ] ] ] 6 => array:3 [ "identificador" => "bib0085" "etiqueta" => "7" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Prevention and management of adverse events related to regorafenib" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "M. De Wit" 1 => "C.B. Boers-Doets" 2 => "A. Saettini" 3 => "K. Vermeersch" 4 => "C.R. de Juan" 5 => "J. Ouwerkerk" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s00520-013-2085-z" "Revista" => array:6 [ "tituloSerie" => "Support Care Cancer." "fecha" => "2014" "volumen" => "22" "paginaInicial" => "837" "paginaFinal" => "846" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/24337717" "web" => "Medline" ] ] ] ] ] ] ] ] 7 => array:3 [ "identificador" => "bib0090" "etiqueta" => "8" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Clinical management of regorafenib in the treatment of patients with advanced colorectal cancer" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:7 [ 0 => "J. Sastre" 1 => "G. Argilés" 2 => "M. Benavides" 3 => "M. Benavides" 4 => "J. Feliú" 5 => "P. García-Alfonso" 6 => "R. García-Carbonero" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1007/s12094-014-1212-8" "Revista" => array:7 [ "tituloSerie" => "Clin Transl Oncol." "fecha" => "2014" "volumen" => "16" "paginaInicial" => "942" "paginaFinal" => "953" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25223744" "web" => "Medline" ] ] "itemHostRev" => array:3 [ "pii" => "S0735109703014049" "estado" => "S300" "issn" => "07351097" ] ] ] ] ] ] ] 8 => array:3 [ "identificador" => "bib0095" "etiqueta" => "9" "referencia" => array:1 [ 0 => array:1 [ "referenciaCompleta" => "Sanz Motilva V. Patología Cutánea en paciente sometido a terapias frente a dianas moleculares. Simposio. Introducción a la dermatonocología. 41 Congreso Nacional de la Academia Española de Dermatología y Venereología (AEDV). Valencia, June 5-8, 2013." ] ] ] 9 => array:3 [ "identificador" => "bib0100" "etiqueta" => "10" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Chemotherapy-induced acral erythema: A clinical and histopathologic study of 44 cases" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Hueso" 1 => "O. Sanmartín" 2 => "E. Nagore" 3 => "R. Botella-Estrada" 4 => "C. Requena" 5 => "B. Llombart" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Actas Dermo-Sifiliográficas." "fecha" => "2008" "volumen" => "99" "paginaInicial" => "281" "paginaFinal" => "290" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/18394404" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010700000001/v2_201704190205/S1578219015003145/v2_201704190205/en/main.assets" "Apartado" => array:4 [ "identificador" => "6157" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Case and Research Letters" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010700000001/v2_201704190205/S1578219015003145/v2_201704190205/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219015003145?idApp=UINPBA000044" ]
| año/Mes | Html | Total | |
|---|---|---|---|
| 2024 Noviembre | 10 | 13 | 23 |
| 2024 Octubre | 85 | 55 | 140 |
| 2024 Septiembre | 99 | 35 | 134 |
| 2024 Agosto | 128 | 91 | 219 |
| 2024 Julio | 94 | 47 | 141 |
| 2024 Junio | 92 | 56 | 148 |
| 2024 Mayo | 85 | 39 | 124 |
| 2024 Abril | 110 | 33 | 143 |
| 2024 Marzo | 116 | 22 | 138 |
| 2024 Febrero | 107 | 32 | 139 |
| 2024 Enero | 105 | 31 | 136 |
| 2023 Diciembre | 90 | 37 | 127 |
| 2023 Noviembre | 118 | 38 | 156 |
| 2023 Octubre | 123 | 45 | 168 |
| 2023 Septiembre | 109 | 29 | 138 |
| 2023 Agosto | 71 | 17 | 88 |
| 2023 Julio | 112 | 48 | 160 |
| 2023 Junio | 74 | 30 | 104 |
| 2023 Mayo | 75 | 26 | 101 |
| 2023 Abril | 90 | 32 | 122 |
| 2023 Marzo | 83 | 29 | 112 |
| 2023 Febrero | 65 | 32 | 97 |
| 2023 Enero | 53 | 35 | 88 |
| 2022 Diciembre | 80 | 56 | 136 |
| 2022 Noviembre | 49 | 30 | 79 |
| 2022 Octubre | 42 | 22 | 64 |
| 2022 Septiembre | 47 | 55 | 102 |
| 2022 Agosto | 29 | 52 | 81 |
| 2022 Julio | 39 | 45 | 84 |
| 2022 Junio | 46 | 41 | 87 |
| 2022 Mayo | 67 | 36 | 103 |
| 2022 Abril | 59 | 37 | 96 |
| 2022 Marzo | 71 | 49 | 120 |
| 2022 Febrero | 53 | 42 | 95 |
| 2022 Enero | 55 | 38 | 93 |
| 2021 Diciembre | 47 | 35 | 82 |
| 2021 Noviembre | 80 | 53 | 133 |
| 2021 Octubre | 65 | 51 | 116 |
| 2021 Septiembre | 72 | 37 | 109 |
| 2021 Agosto | 58 | 26 | 84 |
| 2021 Julio | 45 | 33 | 78 |
| 2021 Junio | 53 | 32 | 85 |
| 2021 Mayo | 66 | 33 | 99 |
| 2021 Abril | 98 | 26 | 124 |
| 2021 Marzo | 75 | 24 | 99 |
| 2021 Febrero | 69 | 34 | 103 |
| 2021 Enero | 44 | 27 | 71 |
| 2020 Diciembre | 36 | 21 | 57 |
| 2020 Noviembre | 68 | 18 | 86 |
| 2020 Octubre | 72 | 14 | 86 |
| 2020 Septiembre | 40 | 14 | 54 |
| 2020 Agosto | 30 | 23 | 53 |
| 2020 Julio | 20 | 21 | 41 |
| 2020 Junio | 42 | 27 | 69 |
| 2020 Mayo | 41 | 26 | 67 |
| 2020 Abril | 34 | 16 | 50 |
| 2020 Marzo | 29 | 23 | 52 |
| 2020 Febrero | 2 | 3 | 5 |
| 2020 Enero | 0 | 1 | 1 |
| 2019 Diciembre | 0 | 1 | 1 |
| 2019 Octubre | 0 | 3 | 3 |
| 2019 Mayo | 2 | 2 | 4 |
| 2019 Abril | 0 | 3 | 3 |
| 2019 Marzo | 0 | 5 | 5 |
| 2018 Diciembre | 3 | 3 | 6 |
| 2018 Noviembre | 3 | 0 | 3 |
| 2018 Octubre | 4 | 0 | 4 |
| 2018 Septiembre | 7 | 2 | 9 |
| 2018 Agosto | 0 | 5 | 5 |
| 2018 Julio | 0 | 3 | 3 |
| 2018 Junio | 0 | 1 | 1 |
| 2018 Mayo | 0 | 3 | 3 |
| 2018 Marzo | 1 | 1 | 2 |
| 2018 Febrero | 40 | 6 | 46 |
| 2018 Enero | 32 | 5 | 37 |
| 2017 Diciembre | 47 | 12 | 59 |
| 2017 Noviembre | 39 | 13 | 52 |
| 2017 Octubre | 32 | 19 | 51 |
| 2017 Septiembre | 29 | 10 | 39 |
| 2017 Agosto | 30 | 9 | 39 |
| 2017 Julio | 21 | 15 | 36 |
| 2017 Junio | 40 | 11 | 51 |
| 2017 Mayo | 41 | 8 | 49 |
| 2017 Abril | 34 | 11 | 45 |
| 2017 Marzo | 21 | 17 | 38 |
| 2017 Febrero | 37 | 8 | 45 |
| 2017 Enero | 33 | 21 | 54 |
| 2016 Diciembre | 39 | 33 | 72 |
| 2016 Noviembre | 41 | 32 | 73 |
| 2016 Octubre | 34 | 31 | 65 |
| 2016 Septiembre | 0 | 10 | 10 |
| 2016 Agosto | 0 | 8 | 8 |
| 2016 Julio | 1 | 4 | 5 |
| 2016 Junio | 0 | 3 | 3 |
| 2016 Mayo | 0 | 1 | 1 |
| 2016 Abril | 0 | 3 | 3 |
| 2016 Marzo | 0 | 3 | 3 |
| 2016 Febrero | 0 | 11 | 11 |
| 2016 Enero | 0 | 6 | 6 |
Mostrar todo
